Mary Eileen Dolan to Paclitaxel
This is a "connection" page, showing publications Mary Eileen Dolan has written about Paclitaxel.
Connection Strength
1.802
-
Pharmacoethnicity in Paclitaxel-Induced Sensory Peripheral Neuropathy. Clin Cancer Res. 2015 Oct 01; 21(19):4337-46.
Score: 0.458
-
Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy. Clin Cancer Res. 2013 Jan 15; 19(2):491-9.
Score: 0.386
-
Whole-genome studies identify solute carrier transporters in cellular susceptibility to paclitaxel. Pharmacogenet Genomics. 2012 Jul; 22(7):498-507.
Score: 0.375
-
Evaluation of inter-batch differences in stem-cell derived neurons. Stem Cell Res. 2016 Jan; 16(1):140-8.
Score: 0.119
-
Modeling chemotherapeutic neurotoxicity with human induced pluripotent stem cell-derived neuronal cells. PLoS One. 2015; 10(2):e0118020.
Score: 0.112
-
Protein quantitative trait loci identify novel candidates modulating cellular response to chemotherapy. PLoS Genet. 2014 Apr; 10(4):e1004192.
Score: 0.106
-
Regulatory polymorphisms in ß-tubulin IIa are associated with paclitaxel-induced peripheral neuropathy. Clin Cancer Res. 2012 Aug 15; 18(16):4441-8.
Score: 0.093
-
Chemotherapeutic-induced apoptosis: a phenotype for pharmacogenomics studies. Pharmacogenet Genomics. 2011 Aug; 21(8):476-88.
Score: 0.088
-
Integration of genetic and functional genomics data to uncover chemotherapeutic induced cytotoxicity. Pharmacogenomics J. 2019 04; 19(2):178-190.
Score: 0.035
-
Chemotherapy-induced peripheral neuropathy: Current status and progress. Gynecol Oncol. 2016 Jan; 140(1):176-83.
Score: 0.030